La FDA ha aprobado Mimrylo (rusfertide) para tratar la policitemia vera, un cáncer de la sangre poco frecuente caracterizado por la producción excesiva de glóbulos rojos.

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder First-in-class therapy targets the biology driving red blood cell overproduction in polycythemia vera https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder?utm_medium=email&_hsenc=p2ANqtz-_Z03JHUHwwkmPI2uUDxGZJE3KKl-v418yGNbm_x8_uX6rrRrG5CQI1ZBNBNTgr4bHCKHrqLGhJLxl7bbB2S9PcDhQuSA&_hsmi=144840094&utm_content=144848639&utm_source=hs_email